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Abstract
Oncolytic influenza A viruses with deleted NS1 gene (delNS1) replicate selectively in tumour cells with defective interferon
response and/or activated Ras/Raf/MEK/ERK signalling pathway. To develop a delNS1 virus with specific immunostimulatory
properties, we used an optimised technology to insert the interleukin-15 (IL-15) coding sequence into the viral NS gene
segment (delNS1-IL-15). DelNS1 and delNS1-IL-15 exerted similar oncolytic effects. Both viruses replicated and caused
caspase-dependent apoptosis in interferon-defective melanoma cells. Virus replication was required for their oncolytic
activity. Cisplatin enhanced the oncolytic activity of delNS1 viruses. The cytotoxic drug increased delNS1 replication and
delNS1-induced caspase-dependent apoptosis. Interference with MEK/ERK signalling by RNAi-mediated depletion or the
MEK inhibitor U0126 did not affect the oncolytic effects of the delNS1 viruses. In oncolysis sensitive melanoma cells, delNS1-
IL-15 (but not delNS1) infection resulted in the production of IL-15 levels ranging from 70 to 1140 pg/mL in the cell culture
supernatants. The supernatants of delNS1-IL-15-infected (but not of delNS1-infected) melanoma cells induced primary
human natural killer cell-mediated lysis of non-infected tumour cells. In conclusion, we constructed a novel oncolytic
influenza virus that combines the oncolytic activity of delNS1 viruses with immunostimulatory properties through
production of functional IL-15. Moreover, we showed that the oncolytic activity of delNS1 viruses can be enhanced in
combination with cytotoxic anti-cancer drugs.
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Introduction
Oncolytic viruses destroy selectively tumour cells sparing non-
malignant (normal) cells [1]. During tumorigenesis, cells undergo
multiple changes. This results in alterations of the activation status
of many different signal transduction pathways, such as the Ras/
Raf/MEK/ERK or PI3K/AKT kinase pathways [2] as well as
pathways involved in the antiviral response such as interferon
signalling. These alterations render tumour cells susceptible to
different (engineered) oncolytic viruses while normal cells are not
affected by them.
In order to enhance the anti-cancer properties of oncolytic
viruses, so called ‘‘armed viruses’’ have been developed. In
addition to their oncolytic activities, these viruses encode for
various gene products that exert anti-cancer effects. One approach
is the introduction of genes encoding for pro-apoptotic proteins or
molecules that block constitutively activated oncogenic signalling
pathways [1]. Other viruses encode for gene products that exert
anti-angiogenic or immunostimmulatory effects [3–6].
The influenza A non-structural protein 1 (NS1) is an interferon
antagonist. Influenza A viruses in which the NS1 gene has been
deleted (delNS1) were shown to specifically lyse interferon-
defective cancer cells or cancer cells that express oncogenic Ras
[7–8]. Furthermore, delNS1 influenza A viruses were shown to
induce immune responses through the activation of cytotoxic T-
lymphocytes (CTLs) and natural killer (NK) cells [9–10]. To
enhance the immunostimulatory properties of delNS1 viruses, we
developed a novel strategy for the generation of transgenic viruses
that stably express cytokines [11]. The influenza A virus genome
consists of 8 gene segments. The proteins NS1 and NEP (formerly
NS2) are encoded on segment 8. The mRNAs for NS1 or NEP are
produced by alternative splicing. We inserted the coding sequence
of several cytokines and chemokines (IL-2, IL-24, CCL20) into
segment 8 of a delNS1 influenza A virus. The resulting viruses
retained their ability to induce the expression of NEP and caused
the production of high levels of corresponding chemokines in
African Green Monkey kidney Vero cells [11].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36506Based on this technology, we here generated a novel delNS1
virus encoding for IL-15 (delNS1-IL-15). IL-15 was suggested to
be superior and distinct from IL-2 in its potential to generate
tumour-specific CTL and NK cell responses [12–13]. Recently, an
interleukin-15 expressing oncolytic vesicular stomatitis virus
showed increased anti-tumor immune response [6]. We chose
melanoma as model entity for the investigation of the oncolytic
effects and IL-15 expression induced by the delNS1-IL-15 virus.
Melanoma cells are known i) to be sensitive to oncolysis by delNS1
virus [7–8] and ii) NK-cells as well as T-cells were shown to play
crucial roles in the anti-melanoma immune response [14]. The
delNS1-IL-15 virus exerted oncolytic effects and induced apoptosis
in interferon-defective melanoma cells to a similar extent like the
corresponding delNS1 virus. The pro-apoptotic effects of the
delNS1 viruses were enhanced in combination with the cytotoxic
drug cisplatin. In addition, infection of melanoma cells with




Colo-679, IPC298, and IGR-39 cell lines were obtained from
the DSMZ, Braunschweig, Germany. Mewo cells were received
from ECACC, Salisbury, England. All cells were propagated in
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented
with 10% FBS, 100 IU/mL penicillin, and 100 mg/mL strepto-
mycin at 37uC. Cell culture media were purchased from
Biochrome (Berlin, Germany).
Virus preparation
All viruses were generated by reverse genetics as described
before [15]. IVR-116 consists of the PB2, PA, NP, NS and M
genes from H1N1 A/PuertoRico/8/34; the HA and NA genes
from H1N1 A/NewCaledonia/20/99, and the PB1 gene from
H3N2 A/Texas/1/77. The delNS1 viruses used in this study
consist of the same gene segments as IVR-116 but have a deletion
in the NS gene segment (coding for NS1 and NEP by alternative
splicing) resulting in the expression of a truncated, non-functional
NS1 protein (13 N-terminal amino acids of NS1 left). The
interleukin-15 expressing delNS1-IL-15 virus was constructed by
methods decribed previously [11]. In brief, the splicing efficiency
of NS mRNA was improved by modifying the splice acceptor site.
Secretion of the introduced cytokine was achieved by fusing the N-
terminal 13 amino acids of NS1 with the partial murine IgK signal
peptide, followed by the IL-15 cDNA (Figure S1). All viruses were
propagated on Vero (ATCC, CCL-81) cells and cell free virus
aliquots were stored at 280uC. Virus titres were determined as
50% tissue culture infectious dose (TCID50/mL; 50% tissue
culture infectious dose/mL) in confluent Vero cells in 96-well
microtitre plates.
Viability assay
Cell viability was measured by a modified 3-(4, 5-dimethylthia-
zol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) dye reduction
assay. Briefly, cells grown in 96-well plates were infected with
multiplicities of infection (MOIs) ranging from 0.01 to 1. 24, 48, or
72 hours post infection (hpi), MTT-reagent was added and the
plates were incubated for 4 hours at 37uC. Subsequently, a 20%
SDS solution in 1:1 DMF:H2O was added and the plates were
incubated overnight at 37uC. The absorption was detected at a
wavelength of 560 nm and a reference wavelength of 620 nm.
The cell viability was calculated relative to non-infected control
(mock) cells.
Immune staining
Melanoma cells grown in 96-well plates were infected at MOI of
1, 0.1 or 0.01 with the indicated viruses. 24 hpi, cells were
immuno-stained for influenza A nucleoprotein as described before
[16]. Briefly, cells were fixed with ice-cold acetone/methanol
(40:60, Mallinckrodt Baker B.V., Deventer, Netherlands) and
stained using the mouse anti-influenza NP monoclonal antibody
(Millipore, Schwalbach, Germany). Biotin-conjugated secondary
monoclonal antibodies were used and visualisation was performed
using a streptavidin-peroxidase complex and 3-amino-9-ethylcar-




5 Colo-679, IPC298, IGR-39, or MeWo cells were
infected with delNS1 or delNS1-IL-15 at a MOI of 0.1. At the
indicated time points, aliquots of the supernatants were taken and
serial 10-fold dilution steps were performed. Virus titres were
determined by endpoint dilution titration on Vero cells in 96-well
microtitre plates. Plates were incubated for 3–4 days and the wells
were visually analysed for virus-induced cytopathogenic effects.
Virus titres were calculated as 50% tissue culture infectious dose
per millilitre (TCID50/mL).
Determination of the sub-G1 fraction
5610
5 Colo-679, IPC298, IGR-39, or MeWo cells were
infected with delNS1, delNS1-IL-15 or IVR-116 at MOI 1.
48 hpi, cells were fixed and permeabilised with 70% ethanol
overnight at 220uC. The cellular DNA was stained using
propidium iodide (20 mg/mL in PBS) and analysed by flow
cytometry (FACSCalibur, BD Biosciences, Heidelberg, Germany).
Cells with fractional DNA content (‘‘sub-G1’’ cell subpopulation)
are considered to be dead (usually apoptotic) cells. Non-infected
cells served as negative controls, cisplatin-treated (10 mg/mL) cells
as positive control for apoptosis induction.
Caspase activation
Caspase activation was measured using the Caspase-Glo 3/7, 8
or 9 assay (Promega, Mannheim, Germany) following the
manufacturer’s instructions. As control for the induction of
apoptosis, cells were treated with 10 mg/mL cisplatin.
Inhibitors
The caspase-3 inhibitor Z-DEVD-fmk and the pan-caspase
inhibitor Z-VAD-fmk were obtained from R&D systems (Minne-
apolis, USA). To inhibit caspase activation, cells were incubated
for 30 minutes with 80 mM of the inhibitors prior to infection.
Western Blot
For the analysis of the interferon response, 1610
6 cells were
infected at MOI 5. Preincubation with 5610
3 IE/mL Interferon
(IFN) b (betaferon, Bayer-Schering Pharma, Berlin, Germany) for
24 hours served as positive control. The cells were lysed 24 hpi in
Triton X sample buffer and separated by SDS-PAGE as described
before [17]. Proteins were detected using specific antibodies
against b-actin (Sigma, Mu ¨nchen, Germany), STAT1, phospho
STAT1 (both Cell Signalling Technology, Danvers, USA),
STAT2, phospho STAT2 (both Upstate Cell signalling solutions,
New York, Boston, USA), or MxA (Novus Biologicals, Littleton,
USA). For the analysis of ERK and AKT activation, 1610
6 Colo-
679 cells were infected at MOI 1. Protein lysates were taken
24 hpi. Antibodies against ERK1/2, phospho ERK1/2, AKT and
phosphpo AKT (all Cell Signalling Technology, Danvers, USA)
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chemoluminescene using a commercially available kit (GE
Healthcare, Freiburg, Germany).
RNA interference experiments
The synthetic siRNA oligonucleotides ON-TARGETplus
SMARTpool siRNAs targeting ERK1 (encodes ERK1/MAPK3,
NM_002746) or ERK2 (encodes ERK2/MAPK1, NM_002745)
were purchased from Dharmacon (Lafayette, CO, USA). Non-
target siRNA (ON-TARGETplus SMARTpool, Dharmacon) was
used as negative control. Colo-679 cells were transfected by
electroporation using the NeonTM Transfection System (Invitro-
gen) according to the manufacturer’s protocol. Colo-679 cells were
transfected in each case with 2.5 mM siRNA (voltage 1300, width
20, pulses 2). 48 h after transfection, the cells were infected with
the investigated viruses.
Measurement of Interleukin-15 expression (ELISA)
5610
5 Colo-679, IPC298, IGR-39, or MeWo cells were
infected with delNS1 or delNS1-IL-15 at MOI 1 or mock-
infected. Supernatants were collected at the indicated time points.
The amounts of IL-15 were determined using the commercially
available Human Interleukin-Kit (R&D Systems, Wiesbaden,
Germany) according to manufacturer’s protocol.
Measurement of the cytotoxic activity of primary human
NK-Cells
5610
5 Colo-679 cells were non-infected (mock) or infected with
delNS1 or delNS1-IL-15 at MOI 1 and supernatants were
collected 24 hours post infection. The cell culture supernatants
were UV-inactivated for 20 minutes in order to exclude effects
caused by replicating viruses. Primary human NK-cells were
isolated from the blood of healthy volunteers as described before
[18]. NK-cells were then incubated with the supernatants of
infected Colo-679 cells for four days. Thereafter, the NK cell-
mediated tumour cell lysis was determined by a coupled
luminescent method using the aCella-Tox kit (Cell Technology,
Mountain View, CA) as described before [18].
Statistical Analysis
Two groups were compared by student’s t-test, more groups
were compared by ANOVA. Pairwise Multiple Comparison was
performed by Student-Newman-Keuls-Test.
Results
Influence of oncolytic Influenza A viruses on melanoma
cell viability
The IL-15 expressing delNS1-IL-15 influenza A virus was
construced by insertion of the human IL-15 coding sequence into
the NS gene segment, thereby replacing NS1 (Figure S1). The
oncolytic effects of the oncolytic influenza A viruses delNS1,
delNS1-IL-15, and the wildtype NS1 expressing IVR-116 virus
were examined in four different melanoma cell lines: Colo-679,
MeWo, IGR-39, and IPC298. Cells were infected with different
MOIs ranging from 0.01 to 1 and the cell viability was assessed 24,
48, or 72 hours post infection (hpi) by MTT-assay. DelNS1
infection reduced the viability of the investigated cell lines in a
dose- and time-dependent manner relative to the non-infected
control (mock) cells (Figure 1). DelNS1-IL-15 caused similar
tumour cell lysis like delNS1. The effects of the delNS1 viruses on
cancer cell viability were similar to those of the NS1 wild-type
virus IVR-116. All investigated viruses strongly affected the
viability of Colo-679, MeWo, and IPC298 cells, but hardly
affected IGR-39 cell viability. The maximum oncolytic effect was
achieved 72 hpi at MOI 1, when .80% of IPC298 cells and
nearly all Colo-679 or MeWo cells were killed. It was shown
before that delNS1 Influenza viruses showed no toxic or lytic
effects on non-transformed and/or interferon competent cells [7–
8,15]. To ascertain that the newly generated delNS1-IL-15 had no
effect on non-transformed cells, we infected primary human
foreskin fibroblasts (HFF). The viability of HFFs was not affected
after infection with delNS1 or delNS1-IL-15 (Figure S2).
The oncolytic activity of Influenza A viruses depends on
virus replication
To show whether the reduction of melanoma cell viability
depends on virus replication, we observed the expression of virus
nucleoprotein and the production of progeny infectious virus
particles in Colo-679 cells which were sensitive to oncolysis and
the non-sensitive cell line IGR-39. 24 hours after infection with
delNS1, delNS1-IL-15, or IVR-116 at MOI 1 or 0.1 nearly 100%
of Colo-679 cells were infected. At an MOI of 0.01 up to 70% of
Colo-679 cells were infected 24 hpi (Figure 2A). As shown in
Figure 2B all investigated viruses replicated to titres about
10
6TCID50/mL in Colo-679, reaching the peak after 12 to
24 hours. To further elucidate whether oncolysis depends on virus
replication, we infected Colo-679 with UV-inactivated viruses.
Infection with UV-inactivated viruses did not influence cell
viability (Figure S3). The oncolysis-resistant IGR-39 cells were
barely infected (4–6% NP positive cells detectable at MOI 1) and
the titres did not exceed 3610
3TCID50/mL (Figure 2A and 2B).
DelNS1 viruses induce apoptosis in permissive melanoma
cells
Influenza A viruses (avian H5N1 as well as H1N1) are known to
induce caspase dependent apoptosis in different cell types [16,19–
20]. The induction of caspase 3 during influenza virus infection is
known to be important both for virus induced cell death and virus
replication [19]. To study the induction of cell death and the role
of caspases in melanoma cell oncolysis by delNS1 and delNS1-IL-
15, we determined the fraction of sub-G1 cells by flow cytometry
and measured the activation of caspase 3/7, 8 or 9 after virus
infection. DelNS1 and delNS1-IL-15 increased the numbers of
sub-G1 cells by up to 67% in comparison to non-infected cells in
Colo-679 (Figure 3A). The activities of caspase 3/7, caspase 8, and
caspase 9 were significantly induced in delNS1- and delNS1-IL-
15-infected Colo-679 cells (Figure 3B–D). Compared to the
delNS1 viruses, IVR-116 induced lower levels of sub-G1 cells and
less caspase 3/7, 8 and 9 activitation. The infection of IGR-39
with IVR-116, delNS1, or delNS1-IL-15 did neither alter the
number of cells in sub-G1 phase, nor induce caspase 3/7 activity
(Figure 3A and 3E). The caspase 3 inhibitor Z-DEVD-fmk and the
pan-caspase inhibitor Z-VAD-fmk were used to investigate to
which extent the induction of cell death depends on caspase
activation. Both caspase inhibitors reduced the numbers of sub-G1
cells in influenza A virus-infected Colo-679 cell cultures
(Figure 4A). Also, both caspase inhibitors reduced the virus titres
produced by delNS1-infected Colo-679 cells (Figure 4B). To
examine whether the virus-induced apoptosis depends on viral
replication, we used UV-inactivated viruses. Infection of Colo-679
cells with inactivated IVR-116, delNS1, or delNS1-IL-15 viruses
did neither affect the sub-G1 cell numbers (Figure 4A) nor caspase
3/7 activation (data not shown). To investigate the influence of an
apoptosis inducing cytotoxic drug on oncolysis we combined
cisplatin with delNS1 infection. The combination of 0.5 mg/mL
Oncolytic Effects of delNS1-IL-15
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effects in comparison to either single treatment alone (Figure 4C).
Additionally, cisplatin enhanced the delNS1-induced caspase3/7
activation and the delNS1 virus production in Colo-679 cells
significantly (Figure 4D and 4B).
DelNS1 virus causes oncolysis in interferon defective cells
DelNS1 viruses were shown to replicate in cancer cells with
impaired interferon response, but not in interferon competent cells
[8,15]. Thus, we compared the induction of the interferon
response in highly delNS1-permissive (oncolysis-sensitive) Colo-
679 cells and the low-permissive (oncolysis-resistant) IGR-39 cells.
MxA expression is induced by type I and III interferons through
STAT1/STAT2 signalling, but not directly by virus components
or RNA-intermediates [21]. The induction of MxA expression can
therefore be used as a surrogate marker for interferon response.
The infection of Colo-679 cells with delNS1 or delNS1-IL15 did
not induce STAT1 and STAT2 phosphorylation or MxA
expression indicating a lack of interferon signalling (Figure 5).
The infection of IGR-39 cells with delNS1 or delNS1-IL-15,
however, resulted in STAT1 and STAT2 phosphorylation and
upregulation of MxA expression indicating a cellular interferon
response. In comparison to the delNS1 viruses, the IGR-39 cell
interferon response was reduced after infection with wildtype NS1
expressing IVR-116 virus as indicated by decreased levels of
phosphorylated STAT1 and STAT2 and alleviated MxA expres-
sion.
Figure 1. Influence of influenza A virus infection on melanoma cell viability. Cells were infected at a MOI of 1 with IVR-116 (expressing WT
NS1), delNS1 or delNS1-IL-15. MTT-assay was performed after 24, 48, and 72 hours post infection (left panel) or cells were infected at MOIs ranging
from 1 to 0.01 and MTT-Assay was performed 72 hours post infection (right panel). All data represent mean 6 SD of three independent experiments.
*significantly different compared to non-infected control (mock), P,0.05.
doi:10.1371/journal.pone.0036506.g001
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oncolysis
Signal transduction pathways like the Ras/Raf/MEK/ERK
signalling pathway or the PI3K/AKT signalling pathway may be
stimulated by Influenza A infection and may play a role in virus
replication and tumour cell survival [2,20,22]. First, we deter-
mined whether ERK1/2 and/or AKT were activated by delNS1
viruses in Colo-679 cells. Non-infected Colo-679 cells showed
constitutive activation/phosphorylation of ERK1/2, but not of
AKT (Figure 6A). Infection of Colo-679 cells with delNS1 or
delNS1-IL-15 viruses did not influence AKT phosphorylation, but
resulted in increased ERK1/2 phosphorylation. In contrast,
infection with the wild-type NS1 expressing IVR-116 virus
appeared to suppress ERK1/2 phosphorylation and to increase
AKT phosphorylation. To investigate whether activation of
ERK1/2 may be crucial for efficient delNS1 virus-mediated
oncolysis, we performed knock-down experiments with siRNA
directed against ERK1 or ERK2. The analysis of cellular ERK
levels indicated effective down-regulation of ERK1 or ERK2 48 h
after siRNA transfection (Figure S4). Thus, we infected Colo-679
48 h after the transfection procedure with delNS1 (MOI 1). As
shown in Figure 6B the levels of ERK1 or ERK2 remained
diminished during the 24 h of the delNS1 infection experiment in
Colo-679 cells. However, the down-regulation of ERK1 or ERK2
did not affect the delNS1-induced oncolytic effects or delNS1
replication (Figure 6C and 6D). In accordance, U0126, an
inhibitor of the ERK 1/2 up-stream kinases MEK 1/2, did not
impair the oncolytic effects of delNS1 (Figure S5).
DelNS1-IL-15-infected melanoma cells produce
biologically active interleukin-15
To examine whether delNS1-IL-15-infected melanoma cells
produce and secrete IL-15, the amount of IL-15 was measured in
the cell culture supernatants of infected cells by ELISA. As shown
in Figure 7A, IL-15 concentrations of 1140 pg/mL (Colo-679),
70 pg/mL (MeWo), and 200 pg/mL (IPC298) were detected in
the supernatants of delNS1-IL-15-infected melanoma cells. The
maximal IL-15 concentration detected in non-permissive IGR-39
cells was 30 pg/mL. The supernatants of mock- or delNS1-
infected cells did not contain measurable IL-15 levels.
IL-15 can activate T-cells as well as NK cells [13]. To
investigate whether IL-15 expressed by delNS1-IL-15-infected
cells is functional, the supernatant of delNS1-IL-15-infected Colo-
679 cells was examined for its ability to stimulate NK-cells. Freshly
isolated primary human NK-cells were incubated for four days
with cell culture supernatants of non-infected (mock), delNS1-, or
delNS1-Il-15-infected Colo-679 cells. NK-cells incubated with
supernatants of delNS1-IL-15-infected Colo-679 cells displayed a
similar target cell killing efficiency (49% cytotoxicity) like NK cells
stimulated with 100 U of recombinant IL-15 (45% cytotoxicity)
(Figure 7B). In contrast, NK-cells incubated with supernatants of
non-infected (mock) or delNS1-infected cells did not induce NK-
cell-mediated cytotoxicity.
Discussion
Influenza A viruses with complete or partial deletions of the NS
gene segment showed oncolytic activity in cultures and/or animal
models of melanoma, prostate carcinoma, and colon carcinoma
Figure 2. Infection rate and replication kinetics of influenza A viruses. A) Immune staining of infected cells. Cells were infected at MOI 1, 0.1
or 0.01 respectively. Staining for influenza A virus NP antigen expression was performed 24 hours post infection. B) Cells were infected with IVR-116,
delNS1, or delNS1-IL-15 (MOI 0.1). At the given time points, aliquots of the supernatants were taken and the TCID50/mL was determined.
doi:10.1371/journal.pone.0036506.g002
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delNS1-IL-15 influenza A viruses, encoding IL-15 from the NS
gene segment, in comparison to the corresponding delNS1 virus in
a panel of human melanoma cell lines. DelNS1-IL-15 virus
replicated in and induced death of interferon-defective melanoma
cells to a similar extent like the non-modified delNS1 virus. These
results demonstrate for the first time that the expression of foreign
genes from the genome of oncolytic delNS1 viruses does not
interfere with their antitumoural activity.
Influenza A viruses may induce both caspase-dependent or
caspase-independent apoptosis in different cell types including
those derived from different tumor entities [19,24]. The inhibition
of influenza A virus-induced caspase 3 activity prevented virus-
induced cell death and decreased virus replication [19]. In
concordance, we found that caspase 3 is activated during delNS1
virus replication in melanoma cells. Furthermore delNS1 viruses
induced activation of caspase 9 and to a minor extent caspase 8,
suggesting that both, intrinsic and extrinsic apoptotic pathways are
triggered in infected melanoma cells. Notably, the cytotoxic anti-
cancer drug cisplatin enhanced the delNS1 virus-induced apop-
tosis, the delNS1-induced oncolytic effects, and delNS1 virus
replication in melanoma cells. These data support the further
investigation of the anti-cancer effects of delNS1 viruses in
combination with drugs that cause cancer cell apoptosis. A specific
inhibitor of caspase 3 as well as a pan-caspase inhibitor suppressed
virus replication and partially prevented melanoma cells from
Figure 3. Apoptosis induction in influenza A virus-infected melanoma cells. Cells were infected at MOI 1. 10 mg/mL Cisplatin (CDDP) were
used as a control for apoptosis induction. A) The percentage of cells in sub-G1-phase was determined 48 hpi. B–E) Caspase 3/7, 8, or 9 activity was
determined 24 hpi. *significantly different compared to mock, P,0.01, **significantly different compared to delNS1 infection, P,0.01.
doi:10.1371/journal.pone.0036506.g003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36506Figure 4. The role of apoptosis in melanoma cell oncolysis. A) Determination of Colo-679 cells in sub-G1-phase was performed 48 hpi (MOI 1)
by flow cytometry in the absence or presence of the pan-caspase inhibitor Z-VAD-fmk (80 mM) or the caspase 3 inhibitor Z-DEVD-fmk (80 mM). Z-VAD-
fmk or Z-DEVD were added to the cell cultures 30 min prior to virus infection. UV-inactivated viruses served as controls. B) Influence of Z-VAD-fmk
(80 mM), Z-DEVD-fmk (80 mM) or cisplatin (CDDP) on delNS1 replication in Colo-679 cells. Colo-679 cells were treated with the caspase inhibitors
30 min prior to delNS1 (MOI 0.1) infection or treated simultaneously with 0.5 mg/mL cisplatin. Viral titres were determined 24 hpi. C) Cells were
infected with delNS1 MOI 0.1 and treated with 0.5 mg/mL CDDP. Cell viability was determined 48 hpi by MTT-assay and D) Caspase 3/7 was measured
24 hpi. w/o=without treatment. *significantly different compared to non treated P,0.05; **significantly different than delNS1-infection and CDDP-
treatment alone P,0.05.
doi:10.1371/journal.pone.0036506.g004
Figure 5. Induction of interferon response in delNS1-infected melanoma cells. Colo-679 cells and IGR-39 cells were infected with IVR-116,
delNS1 or delNS1-IL-15 respectively (MOI 5). Cells treated with 5000 IU/mL Interferon-b served as control for the induction of interferon response.
Protein levels of STAT1, phosphorylated STAT1 (pSTAT1), STAT2, phosphorylated STAT2 (pSTAT2), MxA, and b-Actin were determined 24 hpi by
Western blot.
doi:10.1371/journal.pone.0036506.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36506virus-induced cell death. The failure of both caspase inhibitors to
completely suppress virus-induced cell death suggests that mech-
anisms other than caspase-dependent apoptosis may be involved in
delNS1 virus-induced cell death. In this context, several wild type
influenza A virus strains were shown to induce necrosis in a human
colon carcinoma cell line while they caused apoptosis in non-
malignant cells [24].
There is evidence that the NS1 protein of influenza A viruses
may act as inhibitor [25–27] or inducer [28–29] of cellular
apoptosis. Among other mechanisms, the anti-apoptotic effects of
NS1 were attributed to the stimulation of the cellular PI3K/AKT
survival pathway [16,30]. The NS1 protein was shown to activate
PI3K/AKT signalling by directly interacting with the p85 subunit
of PI3K [22,31]. In the investigated melanoma cells, delNS1
showed a stronger apoptosis induction than the corresponding
IVR-116 virus expressing wild-type NS1 protein. This may be due
to the decreased activation of the PI3K/AKT pathway by the
delNS1 viruses, since AKT was phosphorylated in IVR-116-
infected cells but not in delNS1-infected cells. Remarkably, PI3K/
AKT activation has been associated with tumour progression and
increased response to antitumoral therapy in malignant cells
including melanoma cells [2].
Activation of the Ras/Raf/MEK/ERK signalling pathway
during influenza infection seems to be important for the succesful
replication of influenza A viruses in host cells [20]. A specific
blockade of the Ras/Raf/MEK/ERK strongly impaired the
growth of different influenza A strains both in vitro and in animal
models [20,32]. It was also shown that Ras/Raf/MEK/ERK
signalling may be involved in oncolysis caused by an influenza A
virus with a partially deleted (truncated) NS gene (TR-NS1 virus)
[9]. The infection of the human prostate cancer cell line LNCaP
with TR-NS1 resulted in ERK1 activation. Since U0126, an
inhibitor of the ERK up-stream kinases MEK 1/2, inhibited the
TR-NS1-induced oncolytic effects this ERK1 phosphorylation was
suggested to be critical for the oncolytic effects of TR-NS1 in this
cell line. However, our results do not provide evidence that Ras/
Raf/MEK/ERK signalling may be of relevance in the context of
the delNS1-mediated oncolytic activity in the investigated
melanoma cells. U0126 treatment did not interfere with the
delNS1-induced oncolytic effects in our experiments. In addition,
siRNA-mediated depletion of ERK1 or ERK2 did not impair
delNS1 replication or delNS1-induced tumour cell lysis. Among
the investigated melanoma cell lines, three display constitutive
activation of the Ras/Raf/MEK/ERK pathway through activat-
ing V600E BRAF mutation or NRAS mutations: Colo-679 (BRAF
V600E mut; Nras wt), IGR-39 (BRAF V600E mut; Nras wt),
IPC298 (Braf wt; Nras Q61K mut) [33–35]. The BRAF and
NRAS wild-type cell line MeWo lacks constitutive activation of
Ras/Raf/MEK/ERK signalling [33,36]. However, there were no
major differences in the sensitivities to delNS1 virus-mediated
oncolysis between cells with constitutively activated Ras/Raf/
MEK/ERK pathway (Colo-679, IPC298) and cells without
deregulated Ras/Raf/MEK/ERK pathway (MeWo). In addition,
V600E Braf mutated IGR-39 cells with constitutively activated
Ras/Raf/MEK/ERK pathway, were insensitive to delNS1-
mediated oncolysis.
Figure 6. Cell signaling pathways activated by oncolytic influenza A viruses in melanoma cells. A) Colo-679 cells were infected with IVR-
116, delNS1 or delNS1-IL-15 respectively (MOI 1). Protein levels of ERK1/2, phosphorylated ERK1/2 (pERK1/2), AKT, phosphorylated AKT (pAKT) and b-
Actin were determined 24 hpi by Western blot. B–D) The role of ERK1/2 phosphorylation in melanoma cell oncolysis by delNS1. Colo-679 cells were
transfected with siRNA directed against ERK1, ERK2, or non-target siRNA and infected at MOI 1 with delNS1 48 hpi. B) Western blot analysis of ERK1
and ERK2 levels. Western blot extracts were taken 24 hpi. C) The cell viability was assesed 48 hpi by MTT assay. D) Virus titres were determined as
TCID50/mL 24 hpi.
doi:10.1371/journal.pone.0036506.g006
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strong interferon response in delNS1-insensitive IGR-39 cells but
failed to induce an interferon response in delNS1-sensitive Colo-
679 cells. These findings suggest that a defect in the interferon
signalling may be relevant for the oncolytic activity of delNS1
viruses in the investigated melanoma cells. However, although the
NS1-expressing IVR-116 virus caused a substantially weaker
interferon response in IGR-39 cells its replication was nevertheless
very limited in this cell line. In this context, low number of IGR-39
cells expressed influenza A virus NP antigen, after infection at
MOI 1. This suggests that the virus infection may be restricted at
early stages of virus replication cycle, such as adsorption and/or
virus uncoating. Thus, also other mechanisms than a lack of
interferon response may play a role in the sensitivity of cancer cells
to oncolytic influenza A viruses.
Recently, we developed a method for the generation of delNS1
vectors that express foreign proteins from the NS gene segment by
the modulation of the splicing efficiency and enhancement of the
expression levels of secreted protein by fusing the N-terminal 13
amino acids of NS1 with an IgK-derived secretion signal peptide
[11]. DelNS1 viruses armed with genes encoding for cytokines
including IL-2 and IL-24 as well as chemokine CCL20 were
shown to replicate in the African green monkey kidney cell line
Vero and to produce the respective proteins [11]. In the present
study, we used this approach for an IL-15 expressing delNS1
vector and showed that this delNS1-IL-15 virus replicates and
Figure 7. Expression of biological active interleukin-15. A) The cell lines were infected with delNS1 or delNS1-IL-15 at MOI 1 or non-infected
(mock). Supernatants were analysed for interleukin-15 by ELISA after the indicated incubation periods. B) Induction of natural killer (NK) cell mediated
tumour cell lysis. Primary human NK-cells were incubated with cell culture supernatants of mock, delNS1-, or delNS1-IL-15-infected Colo-679 cells.
After four days of incubation, NK-cells were analysed for cytotoxicity against non-infected tumour target cells. NK-cells incubated without or with
100 U recombinant IL-15 served as control.
doi:10.1371/journal.pone.0036506.g007
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produced by delNS1-IL-15-infected cancer cells was biologically
active. The supernatants of delNS1-IL-15- (but not of delNS1-)
infected cells stimulated primary NK cell lysis of non-infected
target cells.
In conclusion, the present study describes the generation of an
IL-15-armed oncolytic delNS1 virus and delineates the molecular
mechanisms by which delNS1 viruses including delNS1-IL-15
exert oncolytic effects in human melanoma cells. The oncolytic
effects of delNS1 viruses are enhanced in combination with the
cytotoxic anti-cancer drug cisplatin. In addition, we show for the
first time that a delNS1 virus encoding for a human cytokine
induces the production of a biologically active cytokine in human
tumour cells. These results warrant the further investigation of
delNS1-IL-15 as oncolytic influenza A virus that combine
oncolytic with enhanced immunomostimulatory properties alone
and in combination with cytotoxic drugs.
Supporting Information
Figure S1 Schematic illustration of the influenza A NS
gene segment. The wildtype (wt) NS gene segment (of IVR-116)
is shown in the upper part. The two transcripts (NS1 and NS2/
NEP) are shown. In the lower part the NS1 transcript of delNS1-
IL-15 is shown. SAS, splice acceptor site; SDS, splice donor site;
bp/py, branch point sequence plus 20-nucleotide pyrimidine
stretch; IgK-SP, partial mouse IgKappa signal peptide.
(TIF)
Figure S2 Reduction of cell viability of human foreskin
fibroblasts. Human foreskin fibroblasts (HFF) were infected
with indicated viruses at MOI 1 and cell viability was assessed
72 hpi by MTT assay. Data represent means 6 SD of triplicates of
a representative experiment.
(TIF)
Figure S3 Reduction of cell viability by UV-inactivated
Influenza A viruses. Colo-679 were infected with indicated
UV-inactivated viruses at MOI 1 and cell viability assay (MTT-
assay) was performed 48 hpi. Data represent means 6 SD of
triplicates of a representative experiment.
(TIF)
Figure S4 Efficiency of transfection with siRNAs against
ERK1 and ERK2. Protein extracts were taken 48 hours after
transfection with indicated siRNA and analysed for ERK1 and
ERK2 levels by Western blot.
(TIF)
Figure S5 Influence of MEK1/2 inhibitor U0126 and
delNS1 on cell viability. Colo-679 cells were infected with
delNS1 at a MOI of 0.1 in the absence or presence of the MEK 1/
2 inhibitor U0126 (20 mMo r1 0mM U0126). The cell viability
was determined by MTT assay 48 hours post infection.
(TIF)
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